A Study of SIPLIZUMAB in AILD and LT Patients

Abroad (travel likely)RecruitingPHASE1

Conditions

Autoimmune Liver Disease · Liver Transplant Disorder · Autoimmune Hepatitis · Primary Sclerosing Cholangitis · End Stage Liver DIsease · Cirrhosis, Liver

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States
Contact: Study coordinator (Theresa Lukose, PharmD) · tt2103@cumc.columbia.edu · 212-305-3839
Contact: Principal Investigator (Elizabeth Verna, MD)

Study leads

Elizabeth Verna, MD
Principal Investigator
Columbia University Irving Medical Center/ New York Presbyterian Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

Autoimmune Liver Disease · Primary Sclerosing Cholangitis · Autoimmune Hepatitis

Abroad (travel likely)Recruiting

Cincinnati, United States

MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

Autoimmune Liver Disease · Autoimmune Hepatitis · Primary Sclerosing Cholangitis

Abroad (travel likely)Recruiting

Cincinnati, United States

PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G

Autoimmune Hepatitis · Autoimmune Liver Disease

Abroad (travel likely)Recruiting

Aachen, Germany · Hamburg, Germany

Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome

Autoimmune Hepatitis · Primary Sclerosing Cholangitis · Non-Alcoholic Fatty Liver Disease

Abroad (travel likely)Recruiting

Daejeon, South Korea